The chemical class known as Fer Activators comprises a group of compounds that exert their influence on the Tyrosine-protein kinase Fer (Fer) or its associated signaling pathways. These activators operate through a mechanism of indirect activation, primarily by targeting upstream kinases or signaling molecules that intersect with Fer's activation pathways. By modulating these key elements, Fer activators effectively enhance the activity of Fer in various cellular contexts. This class of compounds plays a crucial role in elucidating the functions and regulatory mechanisms of Fer kinase in cell biology.
Fer activators typically include small molecules that act as kinase inhibitors or modulators of upstream signaling events. For instance, some Fer activators are Src kinase inhibitors. Fer and Src kinases share common signaling pathways, and by inhibiting Src, these compounds relieve the negative regulatory influence Src may have on Fer, thus indirectly leading to the activation of Fer kinase. Similarly, inhibitors of JAK kinases, such as AG 490 or Ruxolitinib, are considered Fer activators, as they prevent JAK-mediated inhibition of Fer in specific cellular contexts, allowing Fer to become more active. Additionally, Fer activators may target other interconnected pathways, like the MAPK and EGFR signaling pathways, where cross-talk occurs with Fer's activation mechanisms. Compounds like Sorafenib or Lapatinib, which inhibit kinases within these pathways, indirectly influence Fer by altering the signaling environment and promoting Fer activation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG 490 is a JAK2 inhibitor that can indirectly activate Fer by preventing the inhibition of Fer by JAK2 in certain cellular contexts. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a potent BCR-ABL and Src family kinase inhibitor. Inhibition of Src can lead to the activation of Fer due to their interconnected signaling pathways. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits BCR-ABL, which can activate Fer through shared downstream signaling pathways, making Fer potentially more active in the absence of BCR-ABL signaling. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a JAK1/2 inhibitor, and inhibition of JAKs can indirectly activate Fer by preventing JAK-mediated inhibition of Fer in certain contexts. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple kinases, including Raf and MAPK pathway components, which can indirectly influence Fer activation through interconnected pathways. | ||||||
Tyrphostin A23 | 118409-57-7 | sc-3554 | 10 mg | $112.00 | 13 | |
AG-18 is a selective inhibitor of Lck, a Src family kinase. Inhibition of Lck can affect downstream signaling events that cross-talk with Fer, potentially activating it. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific p38 MAPK inhibitor. Inhibition of p38 MAPK can indirectly activate Fer, as they are involved in signaling networks that intersect. | ||||||